Healthcare Services

Acute Myocardial Infarction Market Global Report 2026 Market Revenue Growth Expected to Reach $2.06 Billion by 2030 with 5.7% CAGR

March 29, 2026 by Marketing Posting

The Business Research Company’s 2026 market reports include new capabilities such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, aimed at improving the depth, usability, and strategic value of the insights delivered.

How Much Is The Acute Myocardial Infarction Market Expected To Grow In Terms Of Market Value Between 2026 And 2030?

The market size for acute myocardial infarction has demonstrated substantial growth in recent years. Projections indicate it will rise from $1.56 billion in 2025 to $1.65 billion in 2026, achieving a compound annual growth rate (CAGR) of 6.0%. This growth observed in the historic period can be attributed to an escalating prevalence of coronary artery disease, an increase in hospital and specialty cardiac centers, the widespread adoption of electrocardiogram and imaging techniques, enhanced awareness of acute MI symptoms, and the expansion of cardiac research initiatives.

The acute myocardial infarction market is projected to experience robust growth in the coming years, with its size anticipated to reach $2.06 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 5.7%. This expansion during the forecast period is attributable to the development of novel thrombolytic agents, increased utilization of minimally invasive procedures, the adoption of advanced imaging technologies, the proliferation of personalized cardiology treatments, and the integration of AI and big data within cardiac care. Major trends expected in this period include the escalating adoption of percutaneous coronary intervention (PCI) procedures, a rising reliance on advanced cardiac biomarkers for early diagnosis, a growing emphasis on minimally invasive cardiac treatments, the expansion of telecardiology and remote patient monitoring, and enhanced awareness and prevention programs for acute MI.

Download the Free Sample Report to Explore Key Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=23291&type=smp

Which Growth Drivers Are Contributing To The Progress Of The Acute Myocardial Infarction Market?

The increasing number of hypertension cases is projected to propel the expansion of the acute myocardial infarction market moving forward. Hypertension is a health condition defined by persistently high blood pressure, which raises the risk of heart disease, stroke, and other related complications. The prevalence of hypertension cases is growing due to the widespread adoption of inactive lifestyles, often a result of desk jobs, extensive screen time, and minimal physical activity. Hypertension contributes to acute myocardial infarction by harming arteries, encouraging the accumulation of plaque, and escalating the likelihood of blood clots that can obstruct coronary arteries. As an illustration, in September 2025, data from the World Health Organization, a Switzerland-based intergovernmental body, revealed that in 2024, an estimated 1.4 billion adults worldwide, aged 30–79, were affected by hypertension, making up approximately one-third of this age bracket’s population. Therefore, the rising incidence of hypertension is driving the growth of the acute myocardial infarction market.

What Major Segment Divisions Exist Within The Acute Myocardial Infarction Market?

The acute myocardial infarction market covered in this report is segmented –

1) By Type: ST-Elevation Myocardial Infarction (STEMI), Non-ST-Elevation Myocardial Infarction (NSTEMI)

2) By Treatment Type: Thrombolytic Therapy, Percutaneous Coronary Intervention (PCI), Coronary Artery Bypass Grafting (CABG), Medications

3) By Diagnosis Method: Electrocardiogram, Cardiac Biomarkers, Echocardiography, Coronary Angiography, Magnetic Resonance Imaging (MRI), Computed Tomography (CT) Scan

4) By Route Of Administration: Oral Route, Intravenous (IV) Route, Subcutaneous Route, Transdermal Route, Sublingual Route

5) By End User: Hospitals And Clinics, Ambulatory Surgical Centers, Specialty Cardiac Centers, Research Institutes

Subsegments:

1) By ST-Elevation Myocardial Infarction (STEMI): Anterior ST-Elevation Myocardial Infarction (STEMI), Inferior ST-Elevation Myocardial Infarction (STEMI), Posterior ST-Elevation Myocardial Infarction (STEMI), Lateral ST-Elevation Myocardial Infarction (STEMI), Right Ventricular ST-Elevation Myocardial Infarction (STEMI), Extensive (Large) ST-Elevation Myocardial Infarction (STEMI)

2) By Non-ST-Elevation Myocardial Infarction (NSTEMI): Subendocardial Non-ST-Elevation Myocardial Infarction (NSTEMI), Multi-Vessel Non-ST-Elevation Myocardial Infarction (NSTEMI), Silent Non-ST-Elevation Myocardial Infarction (NSTEMI), Recurrent Non-ST-Elevation Myocardial Infarction (NSTEMI)

How Are Trends Shaping The Direction Of The Acute Myocardial Infarction Market?

Major companies engaged in the acute myocardial infarction market are concentrating on securing regulatory authorizations to expand their product portfolios, enhance the effectiveness of treatments, and strengthen their market position. Regulatory approvals represent official permissions from health agencies such as the FDA and EMA, confirming that drugs and medical devices meet safety, efficacy, and quality benchmarks before market introduction. For example, in March 2025, Sungen Biomedical, a China-based biopharmaceutical enterprise, received FDA Fast Track Designation for SGC001, its monoclonal antibody drug, notable as the first globally developed for the emergency treatment of acute myocardial infarction (AMI). This designation recognizes SGC001’s potential to reduce cardiomyocyte apoptosis and improve blood flow in ischemic regions. With promising preclinical results indicating benefits in recovery and reduced mortality, Fast Track status enables expedited FDA communication, accelerating the approval process and ensuring quicker patient access to this innovative AMI therapy.

Which Companies Are Leading Innovation In The Acute Myocardial Infarction Market?

Major companies operating in the acute myocardial infarction market are Johnson & Johnson, F Hoffmann La Roche AG, Merck & Co Inc, Bayer AG, Sanofi SA, Bristol Myers Squibb Company, AstraZeneca plc, Abbott Laboratories, Novartis AG, GSK plc, Eli Lilly and Company, Siemens Healthineers, Koninklijke Philips NV, Boston Scientific Corporation, Daiichi Sankyo Company Limited, Terumo Corporation, MicroPort Scientific Corporation, Pfizer Inc, Boehringer Ingelheim International GmbH, Amgen Inc

Read the full acute myocardial infarction market report here:

https://www.thebusinessresearchcompany.com/report/acute-myocardial-infarction-global-market-report

What Are The Leading Geographic Regions In The Acute Myocardial Infarction Market?

North America was the largest region in the acute myocardial infarction market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the acute myocardial infarction market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Tailored Acute Myocardial Infarction Market Research Report For Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=23291&type=smp

Browse Through More Reports Similar to the Global Acute Myocardial Infarction Market 2026, By The Business Research Company

acute coronary syndrome global market report

https://www.thebusinessresearchcompany.com/report/acute-coronary-syndrome-global-market-report

myocardial ischemia global market report

https://www.thebusinessresearchcompany.com/report/myocardial-ischemia-global-market-report

coronary artery disease global market report

https://www.thebusinessresearchcompany.com/report/coronary-artery-disease-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795